



CLAIMS:


1. A compound, a pharmaceutically acceptable salt or an isotope compound thereof, characterized in that the compound is any of the following compounds:





,



,


,



,



,



,



,



,



I-10 ,



I-12 ,



I-13 ,



I-14 ,



I-16 ,



I-17 ,



I-19 ,



I-20 ,



I-22 ,



I-23 ,



I-24 ,



I-26 ,



I-27 ,


I-28 ,



I-29 ,


I-30 ,



I-31 ,




I-32 ,




I-33 ,




I-34 ,




I-35 ,




I-36 ,




I-37 ,




I-38 ,




I-41 ,




I-42 ,




I-44 ,




I-46 ,




I-47 ,




I-49 ,



I-50 ,




I-52 ,



I-54


or



I-55


.

2. The compound as claimed in claim 1, the pharmaceutically acceptable salt or the isotope compound thereof, characterized in that




I-1


is



or




; or




is a compound with a retention time of 2.262 min or 3.319 min under the following conditions: chromatographic column: IH 25 x 250mm, 10um (Daicel); mobile phase: CO_2 / (MeOH:MeCN=1:1) = 50/50; flow rate: 120 mL/min;


and/or,




is




or




; or




is a compound with a retention time of 12.068 min or 14.283 min under the following conditions: chromatographic column: IC 25 x 250mm, 10um (Daicel); mobile phase: HEX(0.1%DEA):EtOH(0.1%DEA):=50:50; flow rate:50 mL/min;

and/or, 


is



or





;


or 


is a compound with a retention time of 1.299min or 1.936min under the following conditions: chromatographic


column: AS 25 x 250mm, 10um (Daicel); mobile phase: CO_2 / [MeOH(0.2% NH_3(7M in MeOH):MeCN=1:1] = 40/60; flow rate:100 mL/min;


and/or,  is

 or


 ; or

 is a compound with a retention time of 1.759 min or 2.520min under the following conditions: chromatographic column: IH 25 x 250mm, 10um (Daicel); mobile phase: CO_2 / [MeOH:MeCN=1:1] = 50/50; flow rate:120 mL/min;


and/or,  is



or




; or




I-22 is a compound with a retention time of 2.309min or 3.384min under the following conditions: chromatographic column:IH 25 x 250mm, 10um (Daicel); mobile phase: CO_2 / [MeOH:MeCN=1:1] = 50/50; flow rate:120 mL/min;


and/or,




I-12 is






or





;


and/or,  is



 or  ;


and/or,  is

 or



5  ;


and/or,  is


or

;



and/or,



is


or

;


and/or,


is



or

;

and/or,



is



or




;




I-28


and/or, is



or




5 ;




I-33


and/or, is



or




;




I-42


and/or, is



or




;




I-44

and/or, is




or



;

and/or, the pharmaceutically acceptable salt of the compound of I-12 is



.

3. A pharmaceutical composition comprising substance Z and pharmaceutical excipients, wherein the substance Z is a compound as claimed in claim 1 or 2, a pharmaceutically acceptable salt or an isotope compound thereof.

4. A use of substance Z or a pharmaceutical composition as claimed in claim 3 in the preparation of an IRAK4 degrading agent and a medicament for the treatment and/or prevention of Myd88 and/or IRAK4 related diseases, wherein

the substance Z is a compound as claimed in claim 1 or 2, a pharmaceutically acceptable salt or an isotope compound thereof.

5. The use as claimed in claim 4, wherein the IRAK4-related diseases include one or more of chronic lung diseases, autoimmune diseases, inflammatory diseases, tumors, cardiovascular and cerebrovascular diseases and central nervous system diseases.

6. The use as claimed in claim 5, wherein the autoimmune diseases are psoriasis, systemic lupus erythematosus and rheumatoid arthritis.

7. The use as claimed in claim 5, wherein the inflammatory disease is inflammatory bowel disease.

8. The use as claimed in claim 7, wherein the inflammatory disease is ulcerative colitis.

9. The use as claimed in claim 5, wherein the tumors are hematological tumors and solid tumors.

10. The use as claimed in claim 9, wherein the hematological tumors are large B-cell lymphoma and acute and chronic lymphocytic leukemia.

11. The use as claimed in claim 9, wherein the solid tumors are intestinal cancer and skin cancer caused by MYD88 mutations.

12. The use as claimed in claim 5, wherein the cardiovascular and cerebrovascular diseases include stroke and atherosclerosis.

13. The use as claimed in claim 5, wherein the central nervous system disease is primary central nervous system lymphoma.

14. A use of substance Z or a pharmaceutical composition as claimed in claim 3 in the preparation of a medicament, wherein the substance Z is a compound as claimed in claim 1 or 2, a pharmaceutically acceptable salt or an isotope compound thereof; and the medicament is used for treatment one or more of autoimmune diseases, inflammatory diseases, tumors, cardiovascular and cerebrovascular diseases and central nervous system diseases.

15. The use as claimed in claim 14, wherein the autoimmune diseases are psoriasis, systemic lupus erythematosus and rheumatoid arthritis.

16. The use as claimed in claim 14, wherein the inflammatory disease is inflammatory bowel disease.

17. The use as claimed in claim 16, wherein the inflammatory disease is

ulcerative colitis.

18. The use as claimed in claim 14, wherein the tumors are hematological tumors and solid tumors.

19. The use as claimed in claim 18, wherein the hematological tumors are large B-cell lymphoma and acute and chronic lymphocytic leukemia.

20. The use as claimed in claim 18, wherein the solid tumors are intestinal cancer and skin cancer caused by MYD88 mutations.

21. The use as claimed in claim 14, wherein the cardiovascular and cerebrovascular diseases include stroke and atherosclerosis.

22. The use as claimed in claim 14, wherein the central nervous system disease is primary central nervous system lymphoma.